Aktis Oncology, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 15.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 886.02M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Details
| Name | Aktis Oncology, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 79 |
| Founded | 2020 |
| Ipo Date | 2026-01-09 |
| Ceo | Matthew Roden |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US01021M1045 |
| Cusip | 01021M104 |
| Cik | 2035832 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Matthew Roden Ph.D. | President, Chief Executive Officer and Director |
| Todd Foley M.B.A. | Co-Founder and Chairman |
| Dr. Paul L. Feldman Ph.D. | Chief Scientific Officer |
| Dr. Akos Czibere M.D., Ph.D. | Chief Medical Officer |
| Dr. Patrick A. Baeuerle Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Kyle D. Kuvalanka | Chief Financial Officer |
| Dr. Shulamit Ron-Bigger Ph.D. | Chief Operating Officer |
| Dr. Tyler Benedum Ph.D. | Chief Technical Officer |
| Carlos Rodriguez | Executive Director of Corporate Development |
| Dr. Dasa Lipovsek Ph.D. | Vice President and Head of Lead Discovery |
Contact
| Address | 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210, United States |
| Phone | 617 461 4023 |
| Website | https://www.aktisoncology.com |